24 results on '"Garajova Ingrid"'
Search Results
2. ABCB1 overexpression through locus amplification represents an actionable target to combat paclitaxel resistance in pancreatic cancer cells
3. Different Genomic Clusters Impact on Responses in Advanced Biliary Tract Cancer Treated with Cisplatin Plus Gemcitabine Plus Durvalumab
4. Synergic activity of FGFR2 and MEK inhibitors in the treatment of FGFR2-amplified cancers of unknown primary
5. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide population
6. Plasma miR-379 can predict treatment response to FOLFIRINOX and gemcitabine-nab-paclitaxel in advanced pancreatic cancer
7. A pilot study of chlorambucil in pre-treated metastatic pancreatic adenocarcinoma patients bearing germline BRCA or other DNA damage repair system variants
8. Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRCA1-2pv)
9. A multicenter study of skin toxicity management in patients with left-sided, RAS/BRAF wild-type metastatic colorectal cancer treated with first-line anti-EGFR-based doublet regimen: is there room for improvement?
10. Clinicians’ Attitude to Doublet Plus Anti-EGFR Versus Triplet Plus Bevacizumab as First-line Treatment in Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Patients: A Multicenter, “Real-Life”, Case-Control Study
11. The treatment of rectal cancer with synchronous liver metastases: A matter of strategy
12. Heterotopic auxiliary segment 2–3 liver transplantation with delayed total hepatectomy: New strategies for nonresectable colorectal liver metastases
13. Epigenetic and epitranscriptomic changes in colorectal cancer: Diagnostic, prognostic, and treatment implications
14. Perineural Invasion in Pancreatic Ductal Adenocarcinoma: From Molecules towards Drugs of Clinical Relevance.
15. Real-Life Clinical Data of Cabozantinib for Unresectable Hepatocellular Carcinoma.
16. A profile of long-term pancreatic cancer survivors.
17. Prediction Model for Early-Stage Pancreatic Cancer Using Routinely Measured Blood Biomarkers.
18. Real-world impact of olaparib use in patients (pts) with advanced pancreatic cancer (PC) harboring germline BRCA 1/2 (g BRCA) mutations.
19. Postsorafenib systemic treatments for hepatocellular carcinoma: questions and opportunities after the regorafenib trial.
20. Membrane Localization of Human Equilibrative Nucleoside Transporter 1 in Tumor Cells May Predict Response to Adjuvant Gemcitabine in Resected Cholangiocarcinoma Patients.
21. Biological Hallmarks and New Therapeutic Approaches for the Treatment of PDAC.
22. "Open Sesame?": Biomarker Status of the Human Equilibrative Nucleoside Transporter-1 and Molecular Mechanisms Influencing its Expression and Activity in the Uptake and Cytotoxicity of Gemcitabine in Pancreatic Cancer.
23. Clinical features and outcomes of pancreatic cancer patients evaluated for microRNAs as biomarkers of response to treatment during FOLFIRINOX therapy.
24. SAT-477-YI The impact of etiologyon patterns of progression of advanced HCC.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.